trans-AUCB

trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity^[1][2]. IC50 & Target: IC50: 1.3 nM (hsEH), 8 nM (mouse sEH) and 8 nM (rat sEH)^[2] In Vitro: trans-AUCB (t-AUCB; 25-300 μM; 48 hours) suppresses U251 and U87 cell growth in a dose-dependent manner^[1].
trans-AUCB (200 μM; 48 or 96 hours) induces cell-cycle G0/G1 phase arrest in U251 and U87 cells^[1].
trans-AUCB (200 μM; 10 min-4 hours) can increase the phosphorylation levels of p65 after 10 min, reaching to peak after 30 min and lasting for at least 2 hours^[1].
trans-AUCB (200 μM; 48 hours) suppresses U251 and U87 cell growth by activating NF-jB-p65^[1].
trans-AUCB (10 μM; 30 min) efficiently inhibits sEH activities in human glioblastoma cell lines (U251, U87) and human hepatocellular carcinoma cell line (HepG2 cells)^[1].
In Vivo: trans-AUCB (t-AUCB; p.o.; 0.1, 0.5, 1 mg/kg) ameliorates the LPS-induced hypotension in a dose-dependent manner^[2].
trans-AUCB (p.o.; 0.1, 0.5, 1 mg/kg) has t_1/2 values of 20, 30, 15 min and C_max values of 30, 100, 150 nmol/L for p.o. of 0.1, 0.5, 1 mg/kg^[2].
trans-AUCB (s.c.; 1, 3, 10 mg/kg) has t_1/2 values of 60, 85, 75 min and C_max values of 245, 2700, 3600 nmol/L for s.c. of 1, 3, 10 mg/kg^[2].
trans-AUCB (i.v.; 0.1 mg/kg) has t_1/2 values of 70 min and 10 hours for distribution (α) and elimination (β) phases. trans-AUCB has a CL of 0.7 L/h•kg and a V_dss was 17 L/kg^[2].